Firering Strategic Minerals: From explorer to producer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
ASCO abstracts have been published today including this from Scancell - to be presented by study investigator Dr Heather Shaw.
A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial.
Think the submission deadline for the abstract was February but will be interesting to see whether the poster has any updated results.
Click on title for full abstract
https://meetings.asco.org/abstracts-presentations/search?query=*&q=durrant&sortBy=Relevancy&filters=%7B%22meetingTypeName%22:%5B%7B%22key%22:%22ASCO%20Annual%20Meeting%22%7D%5D,%22meetingYear%22:%5B%7B%22key%22:2024%7D%5D,%22mediaType%22:%5B%7B%22key%22:%22Abstracts%22%7D%5D%7D&intcmp=cc_ascoorg_am_view-abstracts_site_meeting-carousel_all__glob_042424_052324_carousel_viewtitles_aware_text_view-abstracts
Reasonable I think, to expect an ASCO attendance related RNS in the next few days. Fascinating to consider what impact the conference attendance bandwagon might be having on the future direction and prospects of the company.
I don't think they would announce groundbreaking results in a poster that is not even presented by the CEO but here's hoping
Scinv-_temp
The biggest oncology conference on the planet - hard to think of a better place to do it!
Having said that, I'm not suggesting for one second that they'll be presenting full results for the SCOPE study, it's too early but they may present updated data from more patients.
RNS says 13 patients
'Scancell will be presenting a poster highlighting data from its open-label Phase 2 SCOPE trial, investigating its cancer vaccine, SCIB1, in combination with checkpoint inhibitors (CPIs) in advanced melanoma. Exceptional results from the first 13 patients receiving SCIB1 have already been demonstrated, with an objective response rate of 85%.'
Scinv....
The usual ambiguous RNS... depending upon how you "read" the RNS ...it's only telling us in the RNS that the results of the first 13 patients are excellent....we may / may not get any more info .
Scancell will be presenting a poster highlighting data from its open-label Phase 2 SCOPE trial, investigating its cancer vaccine, SCIB1, in combination with checkpoint inhibitors (CPIs) in advanced melanoma. Exceptional results from the first 13 patients receiving SCIB1 have already been demonstrated, with an objective response rate of 85%.
Berm...indeed... the RNS doesn't say the poster is based on the 13 pts...
š¤£š¤£š¤£
The way I read it āExceptional results from the first 13 patients receiving SCIB1 HAVE ALREADY been demonstratedā¦..ā Strongly suggests to me updated data will be presented.
@jambaion - agree with your interpretation.
And on the AACR RNS they said "Previously..." which was even stronger. Bermuda is feeding you balls
I actually agree with Scinv.
We will be updated on the Scope trial when Lindy is ready to update.
That may be when all patients have been recruited (43 patients) and it may be when Lindy feels there is enough scan data from a minimum number of patients.
But we are getting closer to an update
Re Asco, Bermuda 07.11 suggests " but they may present updated data from more patients", Violin points out some ambiguity and posts", we may / may not get any more info" and Jambo and WTP seem to concur.
Scinv also seems to concur but makes a comment about 'balls' which is confusing given Bermuda's position in the earlier post.
Ray I'm not sure which polarity of Scinv's view you agree with but I'm in the camp that hopes for and maybe expects an update of some sort on the day.
Time will tell. GLA
"Bermuda is feeding you balls"
Yes, yours probably.
"Exceptional results from the first 13 patients receiving SCIB1 have already been demonstrated, with an objective response rate of 85%."
Could be taken either way but I wouldn't say "strongly" on one or the other.
The term "ALREADY been demonstrated" is a teaser
already been demonstrated....... and we have some more positive data
Or
Already been demonstrated....... and we're going to tell you the same again
Which is more likely?
Hi TF
Just to clarify, I am with Scinv in that we do not know when new data is to be presented.
It may be prior or straight after the ASCO presentation or it may be at some other date.
I'm certainly not with Scinv on the statement "Bermuda is feeding you balls"
My gut feel.. FWIW, is that we are close enough to the full results now, that Scancell will be holding back for the full reveal when they have all the results in. Releasing more data at this stage just dilutes the impact. I think they are going headline grabbing in Q4.
Konar, I think I would agree with you. The intensity of poster presentations and conference attendance, I feel is building up to a full results reveal. I would hope that the PR machine has also been refuelled ready to create a proper splash.
I think we may hear more about Modi-1 and glymabs as fillers before the finale.
27 patients immunised as of May. Not even the 34 required if ORR remains at 85%. Sadly, this is starting to look a lot like SNG. Sigh.
Is burble the same person as Bermuda? Surely he knows that we need minimum 34 patients for the "full results" and that we only have 27 so far (remember we need 3 months after immunisation fornthe first read-out). In my humble experience it is the pumpity pump people who sell first.
Scinv - no we're not the same person. Berm is somebody I hold in v.high regard on this board. I wouldn't call them a pumpity pump person - just a very measured and balanced person who knows a lot about SCLP.
Scinv - you sound familiar. Are you another incarnation of old Aimbig? Or one of that crew perhaps?
Obviously a disrupter so gone to the world of the green bin.
Yes me too Chester . . . .